Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

Gilead Sciences, Inc. (GILD) reported mixed results in the fourth quarter as earnings missed expectations while sales surpassed the same.GILD’s fourth-quarter adjusted earnings of $1.72 per share missed the Zacks Consensus Estimate of $1.76 but increased from $1.67 in the year-ago quarter. The year-over-year increase was due to lower total costs and expenses.Total revenues of $7.1 billion beat the Zacks Consensus Estimate of $7 billion on better-than-expected Veklury (remdesivir) sales, due to an uptick in ...